While You Were Starting the Wild Rumpus

Hope you had a good weekend. We've rounded up a few Wild Things so you don't have to spend the price of admission looking for them. Of course we hear the movie is pretty good, too.

• Wild and crazy technology: Did you know? You e-book people can now read The IN VIVO Blog on Kindle. See too our friends at OTC Today, also available on your funky future book machine. AZ chief David Brennan loves his Kindle, according to this Times profile, probably because he can get IVB on it.
  
• Wild geese, chased: Via Bloomberg, President Obama describes insurance industry anti-reform tactics: "It's smoke and mirrors. It's bogus." To which Bill S. Preston, Esq. and Ted "Theodore" Logan respond: "duude." (Bill & Ted presumably also totally bummed about swine flu's affects on nation's beer pong habits. No way? Way.)
  
• Not so wild about the idea: FDA completely responds to Genentech and Biogen Idec regarding earlier use of Rituxan in rheumatoid arthritis. Let us summarize for you: "no, because of PML." UPDATE: FDA also looking for more information on Novartis/Vectura COPD hopeful QAB149, reports Reuters. UPDATING THE UPDATE: And Amgen's denosumab makes it three big Complete Responses, the biggest saved for last. We'll have more later in 'The Pink Sheet' DAILY.
  
• O(be)s(e)car Wilde: (OK that's one's a stretch.) The NYT has a good take on the race to bring a new obesity drug to market, starring Vivus, Orexigen, and Arena. (Hey we said there'd be lots of these ...)
• Mr. Uninsured's Wild Ride: In WaPo, a first person account of what it's like to be 51 and well (and well-off) but uninsured.
  
• P.S. What's a pirate's favorite Annual Scientific Meeting? A-C-Arrrrrrrr! Get all the headlines here. Thanks folks, we're here all week. Tip your waitresses.
• UPDATE: Wild Pitch: Bnet takes hypey but vowel-rich biotech Epeius down a peg.